Comparing the current results to its competitors, Ocugen Inc reported Revenue increase in the 2 quarter 2026 by 8.38 % year on year. The sales growth was above Ocugen Inc 's competitors' average revenue growth of 1.81 %, achieved in the same quarter.
Ocugen Inc 's Comment on Competition and Industry Peers
The biotechnology industry is characterized by intense competition driven by rapid technological advancements and a strong focus on intellectual property. Competitors include major pharmaceutical companies, specialty pharmaceutical firms, biotechnology companies, academic institutions, government agencies, and other research organizations. In the U.S. regenerative medicine sector, specifically articular cartilage repair, NeoCart faces competition from Vericel Corporation's MACI, the only FDA-approved autologous chondrocyte implantation (ACI) product in the U.S., and Aesculap Biologics, LLC's NOVOCART 3D, which is in Phase 3 clinical trials. In the COVID-19 vaccine market, competitors include Pfizer Inc./BioNTech SE, Moderna, Inc., AstraZeneca PLC, Novavax, Inc., Sinovac Biotech Ltd., Gamaleya Research Institute of Epidemiology and Microbiology, and the Center for Genetic Engineering and Biotechnology. These vaccines have received authorization or approval in at least one country within the Ocugen Mucosal Vaccine Territory and are administered intramuscularly. CanSinoBIO's Convidecia Air is noted as an intranasal vaccine.
With revenue growth of 8.38 % within Overall company, Ocugen Inc achieved improvement in market share, within Overall company to approximately 0.01 %. << More on OCGN Market Share.
*Market share is calculated based on total revenue.
November 19, 2024
The recent announcement from Ocugen, Inc. regarding their preliminary findings from the OCU410 ArMaDa clinical trial sheds light on a potential breakthrough in treating geographic atrophy (GA), secondary to dry age-related macular degeneration (dAMD). As the prevalence of dAMD continues to rise globally, innovative therapies like OCU410 are pivotal in paving the way for better management of this debilitating condition. Overview of the Study Ocugen s Phase 1/2 OCU410 ArMaDa trial aimed to assess the safety and efficacy of OCU410, a novel modifier gene therapy, in individuals suffering from GA due to dAMD. This initial stage of the trial was focused on dose escalation, a critical step in establishing not only ...
August 5, 2024
Precision Medicine Advancements: Ocugen, Inc. s Expanded Access Program for Retinitis Pigmentosa Receives FDA Green LightMALVERN, Pa., Aug. 05, 2024 In a significant stride towards the treatment of retinitis pigmentosa (RP), Ocugen, Inc. (NASDAQ: OCGN), a trailblazing biotechnology company championing novel gene and cell therapies, today announced the U.S. Food and Drug Administration (FDA) has approved its Expanded Access Program (EAP) for OCU400a. This initiative is aimed at adult patients aged 18 and older diagnosed with RP, a debilitating eye condition characterized by progressive vision loss.Retinitis pigmentosa, an inherited disorder, affects approximately 1 in 4,000 people globally, leading to the ...
June 20, 2024
Ocugen, Inc. Makes Critical Advances with Phase 3 liMeliGhT Clinical Trial for OCU400; First Patient Successfully DosedMALVERN, Pa., June 20, 2024 In a milestone achievement underscoring its innovative approach to treating retinal diseases, Ocugen, Inc. (NASDAQ: OCGN), a pioneering biotechnology firm specializing in the development and commercialization of cutting-edge gene and cell therapies as well as vaccines, has announced the dosing of the first patient in its pivotal Phase 3 liMeliGhT clinical trial for OCU400. This experimental gene therapy product is being specifically designed to address the multifaceted challenges posed by retinitis pigmentosa (RP).Retinitis pigmentosa is a group of rare genetic...
June 5, 2024
Imminent Deadline Approaches for Ocugen Investors to Participate in Securities Class Action, Investigated by Faruqi and Faruqi, LLP New York, June 5, 2024 Faruqi and Faruqi, LLP, a preeminent national securities law firm, is currently undertaking an inquiry into potential claims against Ocugen, Inc. (henceforth referred to as Ocugen or the Company), which is publicly listed on the NASDAQ under the ticker symbol OCGN. Investors are hereby reminded of the looming deadline of June 10, 2024, to motion for the lead plaintiff role in a recently instituted federal securities class action lawsuit against the Company.As a distinguished firm in the realm of securities litigation, Faruqi and Faruqi, LLP brings consid...
May 31, 2024
Ocugen Achieves Key Milestones in Advancing Gene Therapy Programs for Geographic Atrophy and Retinitis Pigmentosa MALVERN, Pa., May 31, 2024 - Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a forefront contender in biotechnology dedicated to pioneering novel gene and cell therapies alongside vaccines, has recently made significant progress in its clinical development initiatives. The advancements span two promising gene therapy products OCU410 and OCU400 targeting debilitating eye diseases: geographic atrophy (GA) and retinitis pigmentosa (RP), respectively.Ocugen has ventured into new territory with its cutting-edge OCU410 (AAV5-hRORA), a modifier gene therapy candidate poised to address GA, an advanc...
May 28, 2024
The esteemed Pomerantz Law Firm has recently announced the initiation of a class action lawsuit against Ocugen, Inc. (NASDAQ: OCGN). Shareholders who have invested in the company are strongly encouraged to contact Danielle Peyton, a representative of Pomerantz Law Firm, to participate in the legal proceedings. The law firm can be reached at newaction@pomlaw.com or 646-581-9980, or toll-free at 888.4-POMLAW. Those interested in this lawsuit are requested to include their mailing address, telephone number, and the number of shares purchased in their correspondence.The Class Action Lawsuit Against Ocugen, Inc.:Pomerantz Law Firm, known for its dedication to shareholder rights, has taken the initiative to file a...
April 10, 2024
In an exciting development for biotechnology company Ocugen, Inc., the European Medicines Agency s Committee for Medicinal Products for Human Use (CHMP) has offered positive scientific advice regarding the approval pathway for OCU400Modifier gene therapy. This therapy targets patients with a broad indication of retinitis pigmentosa (RP), an inherited degenerative eye disease. The review covered the study design, endpoints, and planned statistical analysis of the pivotal OCU400 Phase 3 liMeliGhT clinical trial, conducted in the United States. The approval for submission of a Marketing Authorization Application (MAA) in Europe signifies a significant milestone for Ocugen.Facts and Assessment:The acceptance of ...
April 8, 2024
Ocugen, Inc. Receives FDA Clearance for Phase 3 Clinical Trial of OCU400, the First Gene Therapy for Retinitis PigmentosaGene therapy is an exciting field in biotechnology that holds immense potential for treating a wide range of diseases. Ocugen, Inc., a leading biotechnology company, has recently announced a major milestone in this field with the clearance of an Investigational New Drug (IND) amendment by the U.S. Food and Drug Administration (FDA). This clearance paves the way for the initiation of a Phase 3 clinical trial of OCU400, a groundbreaking modifier gene therapy product candidate for retinitis pigmentosa (RP).Retinitis pigmentosa is a group of rare genetic disorders that result in the progressiv...
February 28, 2024
Ocugen, Inc. (NASDAQ: OCGN), a leading biotechnology company dedicated to the development and commercialization of innovative gene and cell therapies and vaccines, recently announced the availability of its Clinical Showcase webcast on February 21, 2024. This noteworthy event shed light on the cutting-edge advancements in Ocugen s research and development efforts. In this article, we explore the key takeaways from this webcast and delve into the company s potential impact on the field of drug discovery.Webcast Insights:During the Clinical Showcase webcast, Ocugen presented a comprehensive overview of its ongoing research and pipeline. The company s primary focus lies in unraveling the potential of gene and c...
January 31, 2024
In what is a landmark development, Ocugen, Inc., a trailblazer in the biotechnology industry specializing in novel gene and cell therapies, has announced its entry on the stage of the Pharma Market Research Conference (PMRC) 2024. The announcement comes straight from the company s headquarters in Malvern, PA., and has been eagerly anticipated by stakeholders in the pharmaceutical and healthcare industry.Dr. Shankar Musunuri, the Chairman, Chief Executive Officer, and Co-founder of Ocugen, is set to deliver the keynote address on Future Innovations in Healthcare: From Dreaming to Community Health at the prestigious PMRC. The conference is scheduled as a two-day event from February 7 to 8, 2024, based at Newar...
Ocular Therapeutix Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for diseases and conditions of the eye. They utilize their proprietary hydrogel technology to design and manufacture sustained-release treatments that can be administered during routine eye exams and eliminate the need for patient compliance with eye drops.
Opthea Limited operates as a clinical stage biotechnology company, primarily focused on the development of novel therapies for the treatment of eye diseases. The company pursues its business model by leveraging its expertise in the discovery and development of innovative therapeutics, while collaborating with strategic partners and conducting clinical trials to bring its products to market.
Outlook Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing monoclonal antibody-based therapies for various ophthalmic indications. Their business model revolves around leveraging their expertise in developing cost-effective, innovative treatments that address unmet medical needs in the ophthalmic market.
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Sources:
Ocugen Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Ocugen Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
